Sanofi Pasteur announced the results of a Phase 3 trial with its HIV prime vaccine, ALVAC HIV (recombinant canarypox vCP1521) in combination with the booster AidsVax B/E (recombinant gp120 vaccine, from VaxGen). This trial involving more than 16,000 adult volunteers (18-30 years of age) in Thailand demonstrated that the prime-boost combination of ALVAC HIV and AidsVax B/E vaccines was safe and modestly effective in preventing HIV infection. Final results announced by the trial sponsor – the U.S. Army Surgeon General – demonstrated this investigational HIV vaccine regimen lowered the rate of HIV infection by 31.2% compared with placebo.
ALVAC HIV is a live attenuated recombinant canarypox virus expressing gene products from HIV. AidsVax consists of recombinant gp120 protein found on the surface of HIV.
For more information call (800) VACCINE or visit www.sanofipasteur.us.